You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Moodys
Mallinckrodt
Colorcon
McKesson

Last Updated: November 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,661,136

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,661,136
Title: 2-halo-2'-fluoro ARA adenosines as antinoplastic agents
Abstract:The present invention is directed to certain 2'-fluoro, 2-substituted purine nucleosides which are toxic to cancerous cell lines.
Inventor(s): Montgomery; John A. (Birmingham, AL), Secrist, III; John A. (Birmingham, AL)
Assignee: Southern Research Institute (Birmingham, AL)
Application Number:08/320,879
Patent Claims: 1. A method for bringing about a cytotoxic effect in a mammalian cancerous cell which comprises contacting said cancerous cell with an effective amount of a cytotoxic compound having the formula ##STR6## wherein R, each which may be the same or different, is hydrogen or a protecting group; wherein Z is a selected from the group consisting of F, Cl, and Br; and pharmaceutically acceptable salts thereof.

2. A method according to claim 1 which comprises contacting said cancerous cell with a compound wherein R is a protecting group.

3. A method according to claim 1 which comprises contacting said cancerous cell with compound wherein R is hydrogen.

4. A method according to claim 1 which comprises contacting said cancerous cell with a compound wherein Z is Cl.

5. A method according to claim 1 which comprises contacting said cancerous cell with a compound wherein the compound is 2-Chloro-9-(2-deoxy-2- fluoro-.beta.-D-arabinofuranosyl)-9H-purin-6-amine.

6. A method for inhibiting ribonucleotide reductase and DNA polymerase .alpha. in a mammalian cell which comprises contacting said mammalian cell with of a cytotoxic compound having the formula ##STR7## wherein R, each which may be the same or different, is hydrogen or a protecting group; wherein Z is a halogen selected from the group consisting of F, Cl, and Br; and pharmaceutically acceptable salts thereof.

7. A method according to claim 6 wherein R of said compound is a protecting group.

8. A method according to claim 6 wherein R of said a compound is hydrogen.

9. A method for inhibiting ribonucleotide reductase and DNA polymerase .alpha. in a mammalian cell which comprises contacting said mammalian cell with of a cytotoxic compound having the formula ##STR8## wherein R, each which may be the same or different, is hydrogen or a protecting group; wherein Z is a halogen selected from the group consisting of F, Cl, and Br; and the pharmaceutically acceptable salts thereof.

10. A method according to claim 9 wherein R of said compound is a protecting group.

11. A method according to claim 9 wherein R of said compound is hydrogen.

12. A method according claim 9 wherein said compound is 2- Chloro-9-(2-deoxy-2-fluoro-.beta.-D arabinofuranosyl)-9H-purin-6-amine.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Harvard Business School
McKesson
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.